Skip to main content

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal articles  - Journal Article
Morris, MJ; Armstrong, AJ
Published in: J Clin Oncol
September 20, 2026

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

September 20, 2026

Volume

44

Issue

27

Start / End Page

2648 / 2649

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morris, M. J., & Armstrong, A. J. (2026). Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 44(27), 2648–2649. https://doi.org/10.1200/JCO-26-01356
Morris, Michael J., and Andrew J. Armstrong. “Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol 44, no. 27 (September 20, 2026): 2648–49. https://doi.org/10.1200/JCO-26-01356.
Morris, Michael J., and Andrew J. Armstrong. “Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol, vol. 44, no. 27, Sept. 2026, pp. 2648–49. Pubmed, doi:10.1200/JCO-26-01356.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

September 20, 2026

Volume

44

Issue

27

Start / End Page

2648 / 2649

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis